文献速递肾血管病与高血压慢性肾脏病

常染色体显性多囊肾病的心血管表现与管理

Cardiovascular Manifestations and Management in ADPKD.
PubMed 文献 · Kidney Int Rep · 2023-08-04

本综述基于临床前、临床及流行病学证据,阐述常染色体显性多囊肾病(ADPKD)中心血管疾病的表现与发病机制,重点讨论高血压的复杂病理机制及肾外心脏和血管病变,并介绍针对高血压、左心室肥厚和颅内动脉瘤的ADPKD特异性筛查与管理指南。

要点

  • 心血管疾病是ADPKD患者的主要死亡原因,高血压是最常见且可干预的风险因素。
  • RAAS和polycystin相关内皮功能障碍是主要驱动因素,SNS、NO、ET-1和ADMA可能在不同疾病阶段起关键作用。
  • ADPKD有针对高血压、左心室肥厚和颅内动脉瘤的特异性筛查与管理指南。

核心结论

  • 心血管疾病是ADPKD患者的主要死亡原因,高血压是最常见表现和主要可干预风险因素。
  • ADPKD心血管表现的病理机制复杂,涉及RAAS、polycystin相关内皮功能障碍及SNS、NO、ET-1、ADMA等多因素。
  • ADPKD有针对高血压、左心室肥厚和颅内动脉瘤的特异性筛查与管理指南。

研究设计与样本

  • 本综述综合临床前、临床和流行病学证据,详细阐述ADPKD中高血压及其他肾外心脏和血管疾病的复杂发病机制。

主要发现

  • ADPKD心血管表现多样,包括左心室肥厚、颅内动脉瘤、瓣膜性心脏病和心肌病,但高血压最常见且可干预。
  • 左心室肥厚报告率可能因抗高血压治疗使用而下降。
  • 缺血性心肌病报告患病率可能因生存期延长和慢性病发生率增高而增加。

关键数值与推荐

  • ADPKD特异性筛查与管理指南针对高血压、左心室肥厚和颅内动脉瘤,本综述对此进行了描述。

临床怎么用

  • 临床应关注ADPKD患者的高血压管理,并依据ADPKD特异性指南对高血压、左心室肥厚和颅内动脉瘤进行筛查与管理。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiovascular disease (CVD) is the major cause of mortality in autosomal dominant polycystic kidney disease (ADPKD) and contributes to significant burden of disease. The manifestations are varied, including left ventricular hypertrophy (LVH), intracranial aneurysms (ICAs), valvular heart disease, and cardiomyopathies; however, the most common presentation and a major modifiable risk factor is hypertension. The aim of this review is to detail the complex pathogenesis of hypertension and other extrarenal cardiac and vascular conditions in ADPKD drawing on preclinical, clinical, and epidemiological evidence. The main drivers of disease are the renin-angiotensin-aldosterone system (RAAS) and polycystin-related endothelial cell dysfunction, with the sympathetic nervous system (SNS), nitric oxide (NO), endothelin-1 (ET-1), and asymmetric dimethylarginine (ADMA) likely playing key roles in different disease stages. The reported rates of some manifestations, such as LVH, have decreased likely due to the use of antihypertensive therapies; and others, such as ischemic cardiomyopathy, have been reported with increased prevalence likely due to longer survival and higher rates of chronic disease. ADPKD-specific screening and management guidelines exist for hypertension, LVH, and ICAs; and these are described in this review.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Sagar PS, Rangan GK. Cardiovascular Manifestations and Management in ADPKD. Kidney Int Rep. 2023. PMID: 37850017. doi:10.1016/j.ekir.2023.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。